Compounds > thiazoles
Page last updated: 2024-08-21

thiazoles and azd 6244

thiazoles has been researched along with azd 6244 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A1
Chen, CY; Chen, YC; Cheng, YW; Lee, H; Lee, MC; Wu, DW; Wu, JY; Wu, TC1
Ahn, JS; Ahn, MJ; Bae, YH; Jho, EH; Ku, BM; Park, K; Sun, JM1
Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A1

Other Studies

4 other study(ies) available for thiazoles and azd 6244

ArticleYear
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles

2011
Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Oncogene, 2014, Aug-28, Volume: 33, Issue:35

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Paxillin; Phosphorylation; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays

2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays

2015
Survival of pancreatic cancer cells lacking KRAS function.
    Nature communications, 2017, 10-23, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles

2017